+1 Recommend
0 collections
      • Record: found
      • Abstract: found
      • Article: not found

      Coronary artery surgery study (CASS): a randomized trial of coronary artery bypass surgery. Survival data.


      Adrenergic beta-Antagonists, therapeutic use, Clinical Trials as Topic, Coronary Artery Bypass, mortality, Coronary Disease, drug therapy, surgery, Female, Humans, Male, Middle Aged, Random Allocation, Registries, Stroke Volume, United States

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          CASS includes a multicenter patient registry and a randomized controlled clinical trial. It is designed to assess the effect of coronary artery bypass surgery on mortality and selected nonfatal end points. From August 1975 to May 1979, 780 patients with stable ischemic heart disease were randomly assigned to receive surgical (n = 390) or nonsurgical (n = 390) treatment and were followed through April 15, 1983. At 5 years, the average annual mortality rate in patients assigned to surgical treatment was 1.1%. The annual mortality rate in those receiving medical therapy was 1.6%. Annual mortality rates in patients with single-, double-, and triple-vessel disease who were in the surgical group were 0.7%, 1.0%, and 1.5%; the corresponding rates in patients in the medical group were 1.4%, 1.2%, and 2.1%. The differences were not statistically significant. Nearly 75% of the patients had entry ejection fractions of at least 0.50. The annual mortality rates in patients in the surgical group in this subgroup with single-, double-, and triple-vessel disease were 0.8%, 0.8%, and 1.2% and corresponding rates in the medical group were 1.1%, 0.6%, and 1.2%. The annual rate of bypass surgery in patients who were initially assigned to receive medical treatment was 4.7%. The excellent survival rates observed both in CASS patients assigned to receive medical and those assigned to receive surgical therapy and the similarity of survival rates in the two groups of patients in this randomized trial lead to the conclusion that patients similar to those enrolled in this trial can safely defer bypass surgery until symptoms worsen to the point that surgical palliation is required.

          Related collections

          Author and article information



          Comment on this article